Neurology device studies often involve endpoints that can be difficult to quantify and may rely on patient-reported outcomes, functional assessments, and other subjective measures that require thoughtful study design and validation. Conducting neurology device clinical research requires a partner who understands these clinical nuances. This ensures your study protocols include robust investigator training programs, precise endpoint definitions, and minimized drop-out rates.
The MCRA integration combines deep, niche clinical, regulatory, and reimbursement specialization directly with IQVIA’s global scale, data assets, and trial infrastructure. For neurology and neurosurgical innovators, this provides direct access to former FDA reviewers, specialized neurobiostatisticians and research-focused medical advisors. Whether you are developing brain-computer interfaces, deep brain stimulators, neuro-imaging platforms, or surgical robotics, this combined expertise ensures your product strategy is optimized from early-stage regulatory filing through global commercial adoption.
Gaining regulatory clearance is only half the battle; without proper coding, coverage, and payment pathways, hospitals cannot adopt your technology. Payers require solid evidence of long-term functional recovery, fewer/shorter hospitalizations, or reduced reliance on long-term institutional care. Our neurology device reimbursement consultants work directly with our clinical trial designers from day one to ensure your study gathers the exact health economics data required to satisfy global insurance coverage criteria.
